Hot Investor Mandate: US-Based Investment Firm Seeks Life Science Technologies in Areas of Neurology, Ophthalmology, Pulmonology

March 7, 2024 ~ Next Phase Admin ~ Leave a comment

A venture capital firm founded in 2021 with headquarters in the US engages in Seed to Series C rounds, with preference in Series A-C, and focuses on solutions towards a variety of unmet medical needs. The firm is interested in precise, personalized and cost-effective medical technologies and services. While opportunistic regarding sectors, the firm has invested in companies including therapeutics, medtech, diagnostics, and digital health. Typical check sizes range from $3-7M USD on entry with some reserved for follow-ons. The firm can lead investments as well as join syndicates. Although U.S. companies are favored, the firm can invest globally.

The firm is opportunistic in terms of life science and healthcare companies. The firm has a strong focus on ophthalmology, neurology, and pulmonology. For software, the firm has deep ties to the hospital innovation system and looks for opportunities that intersect the patient-provider interface.

The firm typically requires taking a board or observer seat. The firm does not have specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: VC Firm Invests Up to $10M in Early-Stage Technologies Relevant to Precision & Personalized Medicine Based in US & Canada

March 7, 2024 ~ Next Phase Admin ~ Leave a comment

A VC invests in US and Canada-based companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Tagline Competition Winners!

February 29, 2024February 29, 2024 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp Crafting a compelling tagline is more challenging than you would expect – many startups approach it based on what they think sounds good and come out with a slogan that does not give much information on the company. A tagline should give investors a noticeably clear idea of what your company is doing in just 5-7 words. This forms the foundation of a company’s marketing collateral, something we emphasize in our educational content and webinars. It is where we start with the companies we work with, helping them refine their message into a concise, compelling snapshot of the company. It often takes at least 20 versions and edits to land on a good tagline. Gauge your success by sharing it with people unfamiliar with your company – can they accurately describe what your technology is, and what problem/disease you are addressing? If not, go back to the drawing board, or ask for our help!

Ahead of our next RESI event, RESI South, in person in Atlanta March 25, virtual March 26-27, we held a competition for the most compelling tagline, and received quite a few submissions! Below are the six winners – congratulations, and we look forward to seeing you in Atlanta!

Tagline Competition Contest Winners
	Convergence Medical
	Building the world’s first arthroscopic surgical robot.
	Sentrimed
	Creating safer, oral oncology therapies by targeting podoplanin
	BrainStorm Therapeutics
	AI-powered human brain organoid drug discovery engine
	Nanoxort
	Smarter, safer medical imaging – powered by nanotechnology.
	Curanostics
	Revolutionizing infectious disease diagnosis with rapid, precise ML-driven genomic analysis for healthcare.
Light Switch Bio	Light Switch Bio
	Delivering Safety, Maximizing Value: Laser-Guided Drugs Transforming Pharma’s Approach

RESI South Partnering Opens Next Monday

February 29, 2024 ~ Next Phase Admin ~ Leave a comment

By Caitlin Dolegowski, Marketing Manager, LSN

RESI South, in person March 25 in Atlanta at The Whitley Buckhead hotel, followed by two days of virtual partnering on March 26-27 is rapidly approaching, and the partnering platform opens next Monday, March 4. This hybrid conference enables attendees to book both in-person and virtual meetings. The LSN Partnering Platform offers startups the opportunity to search for and identify investors that are a fit for them based on sector, indication, stage of development, and other criteria. Successful partnering takes a lot of work, and the companies that book the most meetings send, on average, over 100 meeting requests to relevant investors, followed by frequent follow-ups. We will be offering a free partnering tutorial next week to provide you with helpful insight into making the most of your time at RESI.

March 5, 2024 12:00 PM ET

The LSN Event Partnering Process – Sign Up

Attending partnering events is a crucial component of a successful fundraising campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow-up message after that.

Partnering Tutorial

Understanding the RESI partnering system and using it to its maximum capabilities can make a large difference in a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are a best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience.

March 6, 2024 12:00 PM ET – Sign Up

March 14, 2024 12:00 PM ET – Sign Up

There is still time to register for RESI South and meet with 250+ active investors in the life science industry.

New RESI Location Brings New Investors Attending

February 29, 2024February 29, 2024 ~ Next Phase Admin ~ Leave a comment

By Momo Yamamoto, Investor Research Analyst, LSN

Life Science Nation(LSN)’s research team has been inviting investors to attend the upcoming RESI South conference and there are some exciting new life sciences, early-stage focused investors who will be joining the RESI South conference.




	MSL Investment

Some new investors attending RESI South include Caduceus Capital Partners, a venture capital firm based in Nashville, TN that invests in early-stage digital health companies across the US. A managing partner of the firm will also be speaking on the Digital Health panel. Joining that panel is another managing partner from Bullet Partners, a private equity and advisory firm headquartered in Atlanta, GA that focuses on digital health and SaaS companies. Monday Capital, a venture capital firm headquartered in New York that invests in biotechnology and digital health companies focused on longevity, blockchain infrastructure, and AI in Seed and early venture rounds, will also be attending for the first time and will be on the AI in Healthcare panel. Pier 70 Ventures, a venture capital firm based in Seattle, WA that invests in digital health and therapeutics companies in seed and early growth rounds will also be joining the discussion on the AI in Healthcare panel as well. GRA Venture Fund, a public-private venture capital fund investing in research-driven, Georgia-based startup companies will also be attending RESI South for the first time in-person. Boyd Street Ventures, a venture capital firm headquartered in Oklahoma that invests in life sciences and healthtech and is preparing to launch its second fund later this year, will be attending in-person. Catalyst by Wellstar, a fund affiliated with Gerogia’s largest healthcare system, and MSL Investments, an early-stage investment firm focused on early-stage medtech and digital health companies, will be attending virtually. Ajinomoto Corporate Venture Capital (Ajinomoto CVC) is the corporate venture arm of Ajinomoto Co., Inc., a leading global company well known for its food products and amino science businesses with over $10B revenue. Ajinomoto CVC was launched in 2020 and has a US office based in Palo Alto, CA. The firm seeks to make equity investments in promising early-stage biotech companies developing therapeutics of novel modalities companies, in mostly Seed and Series A rounds.

Hot Investor Mandate: Global Manufacturing Company With Newly Established CVC Invests in Clinical Stage Devices, Diagnostics, Biomanufacturing, and More

February 29, 2024 ~ Next Phase Admin ~ Leave a comment

A global manufacturing company has a wide range of businesses including analytical instruments, medical devices, and industrial equipment. Recently, the firm has been focusing on healthcare, specifically in clinical diagnostics, and biomanufacturing. Last year, the firm established a corporate venture capital (CVC) department and is looking for strategic partnerships with companies with cutting-edge technology that align with their businesses. The fund will be managed for 10 years with a total investment of ¥5B JPY (~$50M USD). So far, the firm has invested in 3 companies and is looking to expand their investments in the States, though they are open to meeting with global companies. The fund is looking to invest in Pre-Seed to Early rounds but may invest as far as Series A. Typical check size can range from $1-10M USD but can exceed if there is a particularly strong interest in a technology.

In terms of healthcare, the firm is looking to invest in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but consumables as well.

To attract investment from the firm, having a lead investor is desirable.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: VC Firm Invests in USA-Based Medical Device & Diagnostics Companies With Validated PoC

February 29, 2024 ~ Next Phase Admin ~ Leave a comment

A Venture Capital firm is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.